A Podcast on Osimertinib After CRT in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

Show notes

In this podcast, Thanyanan Reungwetwattana from the Division of Medical Oncology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, Kristin A. Higgins from the Department of Radiation Oncology, City of Hope Cancer Center Atlanta, Atlanta, GA, USA, Ignacio Casarini from the Servicio Oncología, Hospital Bernardo Houssay, Mar del Plata, Buenos Aires, Argentina, and Suresh S. Ramalingam from the Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA discuss considerations surrounding the implementation of the LAURA (NCT03521154) regimen (osimertinib after chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer) in clinical practice, including the potential challenges for healthcare professionals and how they may be mitigated.
This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01250-z. All conflicts of interest can be found online.
Open Access: This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.